Home
gibreel ferishta's Library tagged → View Popular
FM radio making rapid strides, revenue expected to touch Rs 800 cr this year
The entry of private players has boosted the fortunes of FM radio in a big way in the country. This has been consistently reflecting in the revenue earned by the industry, which grew to Rs 550 crore last year from Rs 350 crore a year ago. The industry is expected to close with over Rs 800 crore in revenue this year.
Apurva Purohit, president, Association of Radio Operators of India (AROI), and CEO of Radio City 91.1FM, said that FM radio channels are making rapid strides by having a presence in 91 cities as against 30 cities about two years ago. This has resulted in a growth in reach, which is faster than TV, reaching out to over 85 per cent of the Indian audience.
On cost, radio campaign turns out to be 65 per cent less expensive than TV while delivering 64 per cent larger reach. Speaking of print, the same investment on radio delivers 760 spots compared to a 3-print insertions at 11 per cent lower cost.
Ranbaxy buyout awaits CCEA nod
Japan's Daiichi Sankyo's proposal to acquire Ranbaxy will go to the Cabinet Committee on Economic Affairs (CCEA) for approval. Any foreign deal exceeding Rs 600 crore has to be approved by the CCEA under the existing policy.
Industry secretary Ajay Shanker told reporters that he does not see any problems related to the Tokyo-based Daiichi Sankyo's controlling bid on Ranbaxy Laboratories. The takeover is valued at $ 4.6 billion (Rs 19,780 crore).
The open offer by Daiichi to acquire upto 20 per cent of Ranbaxy's shares will close on September 4
Financial Express : Chemists in new deal to beat big retail
he fierce battle in the retail pharma space is set to reach new dimensions, as drug retailers have started entering into exclusive tie-ups with drug manufacturing companies. The All Indian Origin Chemists & Distributors Limited (AIOCDL), the newly formed company with 5 lakh chemists across the country as members, is set to sign an exclusive tie-up with a Mumbai-based drug manufacturer. The deal is seen by many as AIOCDL’s strategic move to thwart the growth of retail pharmacy chains belonging to corporate giants in the country.
According to the deal, the manufacturer, Maneesh Pharma, will supply its drugs exclusively to AIOCDL, and not to other organised pharmaceutical retailers. Vinay Sapte, managing director, Maneesh Pharma, told FE, “We are considering an alliance with AIOCDL. In a couple of days, the model will be finalised.” In a few markets, the drugs will be supplied exclusively to AIOCDL, he added, without refusing to disclose further.
Financial Express : New DGCI system to make life easier for the pharma industry
In an effort to facilitate the fast growing Indian pharma industry to position itself globally, Drugs Controller General of India (DGCI) has initiated a centralised uniform system for various processes of the industry.
“Online real time system for various approvals will be fully operational within two to three,” the new DGCI DrSurendra Singh said, while inaugurating a seminar on ‘How quality pays’, organised by the Indian Drug manufacturing Association.
Singh said 60% of the delays faced by the industry was in getting test licence, export NOC and to get approval for conducting clinical trials and all these delays will be addressed by setting up a system e-governance by digitalising offices (both head office and regional offices) and having interactive portals.
-
In an effort to facilitate the fast growing Indian pharma industry to position itself globally, Drugs Controller General of India (DGCI) has initiated a centralised uniform system for various processes of the industry.
“Online real time system for various approvals will be fully operational within two to three,” the new DGCI DrSurendra Singh said, while inaugurating a seminar on ‘How quality pays’, organised by the Indian Drug manufacturing Association.
Singh said 60% of the delays faced by the industry was in getting test licence, export NOC and to get approval for conducting clinical trials and all these delays will be addressed by setting up a system e-governance by digitalising offices (both head office and regional offices) and having interactive portals.
DGCI office is trying to fix time frame for all the procedures of not more than eight weeks, including issuing of test licenses, NOC for export and clinical trials, in cooperation with the pharma industry.
Canada regulator finds Ayurvedic products harmful
Health Canada, a drug and health regulatory body, has once again said some Ayurvedic products may contain high levels of heavy metals, such as lead, mercury and arsenic. Saying these medicines may pose serious health risks, the Canadian regulator has asked people to exercise caution while purchasing them.
The move is based on an article in the March 2008 edition of the British Columbia Medical Journal, detailing how an adult male had symptoms of vomiting and diarrhoea, believed to have been caused due to heavy metal poisoning by consuming one tablet a day of Puspadhanva Rasa, manufactured by Shri Dhanwantri Ayurvedic Pharmacy of India.
-
Health Canada, a drug and health regulatory body, has once again said some Ayurvedic products may contain high levels of heavy metals, such as lead, mercury and arsenic. Saying these medicines may pose serious health risks, the Canadian regulator has asked people to exercise caution while purchasing them.
<script language="JavaScript">
google_ad_client = 'businessstandard';
//google_ad_client = 'ca-businessstandard_js';
google_ad_width = 200;
google_ad_height = 200;
google_ad_format = "200x200_as";
google_ad_type = "text";
google_ad_channel = "";
//google_color_border = "FFFFFF";
google_color_border = "F7F7F7";
//google_color_bg = "FFFFFF";
google_color_bg = "ffffff";
//google_color_link = "639ACE";
google_color_link = "0253B7";
google_color_text = "000000";
google_color_url = "D63431";
//google_skip = adsenseSkip;
</script>
<script src="http://pagead2.googlesyndication.com/pagead/show_ads.js" type="text/javascript">
</script>The move is based on an article in the March 2008 edition of the British Columbia Medical Journal, detailing how an adult male had symptoms of vomiting and diarrhoea, believed to have been caused due to heavy metal poisoning by consuming one tablet a day of Puspadhanva Rasa, manufactured by Shri Dhanwantri Ayurvedic Pharmacy of India.
-
The study had alleged that 14 of these products, made by Ayurvedic firms, like Dabur, Zandu, Baidyanath, Himalaya and Jalaram, contained harmful levels of lead, mercury and arsenic.
Based on the JAMA study, Health Canada, the UK's drug regulator MHRA and Singapore's regulator HSA had issued warning against Ayurvedic products with high metal content.
The issue also caused India's ministry of health to make heavy metal tests mandatory for herbal, Ayurvedic, Siddha and Unani medicine exports from January 1, 2006. The exported products also have to display on the label whether the heavy metals are within the permissible levels.
Financial Express : India is 2nd largest exporter of fake medicines to EU ...
The following statistics may not give India much reason to cheer. The country is still the second largest counterfeit medicines exporter to the European Union in 2007, although it has forfeited the first position it held in 2006 to Switzerland.
As per data released by the European Commission on Monday, India stands second after Switzerland in the list of top exporters of fake medicines to the EU in 2007 with 35% of the total fake drugs seized. In 2006, India was the leading source of fake drugs exported to the EU.
Next to Switzerland and India, the United Arab Emirates comes third with 15% of the total amount seized, according to the survey titled, '2007 customs seizure of counterfeit goods at EU's external border'. In 2006, India, together with the UAE and China, was responsible for more than 80% of all counterfeit medicines.
-
The following statistics may not give India much reason to cheer. The country is still the second largest counterfeit medicines exporter to the European Union in 2007, although it has forfeited the first position it held in 2006 to Switzerland.
-
Also, in 2005, based on the European Commission's Taxation and Custom Union (TAXUD) statistics, 75% of fake medicines cases originated from India, 7% from Egypt, and 6% from China. According to an earlier EU report, counterfeiters accept crude methods for manufacturing drugs such as filling the capsules with a mixture of brick dust with yellow paint used to mark roads to give it a colour similar to that of genuine medicine and furniture polish to give a nice, shiny finish.
- 1 more annotations...
BIG Entertainment to produce 69 films in 2 yrs
-
Reliance BIG Entertainment on Sunday said that it will produce, distribute and co-produce 69 films in Hindi, English and regional Indian languages over the next two years.
<script language="JavaScript">
google_ad_client = 'businessstandard';
//google_ad_client = 'ca-businessstandard_js';
google_ad_width = 200;
google_ad_height = 200;
google_ad_format = "200x200_as";
google_ad_type = "text";
google_ad_channel = "";
//google_color_border = "FFFFFF";
google_color_border = "F7F7F7";
//google_color_bg = "FFFFFF";
google_color_bg = "ffffff";
//google_color_link = "639ACE";
google_color_link = "0253B7";
google_color_text = "000000";
google_color_url = "D63431";
//google_skip = adsenseSkip;
</script>
<script src="http://pagead2.googlesyndication.com/pagead/show_ads.js" type="text/javascript">
</script>The company also inked a deal with Vinod Chopra Films and Excel Entertainment to produce eight films.
According to industry estimates, the production value of the 69 films will be in excess of Rs 1,200 crore and some of the films will be made in languages like Punjabi, Gujrati, Marathi, Tamil, Telegu and Bengali among others.
74% FDI cap on satellite radio
As part of its recommendations, which are expected to be announced in a few days, the regulator has proposed a one-time entry fee of Rs 2.5 crore and an annual revenue share equivalent to 4 per cent of radio companies' gross revenues.
The licence conditions will also prohibit radio companies from selling commercial airtime to advertisers. Service providers will also need to register every channel they air. News content will be permitted only from state-owned Doordarshan and All India Radio.
The Trai recommendations will impact the radio business of WorldSpace, requiring it to reduce its foreign equity from 100 per cent to 74 per cent and discontinue broadcasting private news channel stations in India other than paying the entry fee and sharing revenue with the government.
-
The Telecom Regulatory Authority of India (Trai), whose ambit also covers the broadcasting business, has prepared guidelines on satellite radio operations that will limit foreign direct investment (FDI) to 74 per cent and introduce licence requirements for transmission and content.
Currently, WorldSpace is the sole satellite radio service provider in the country but it has been operating without a licence in the absence of guidelines for the sector.
-
, the regulator has proposed a one-time entry fee of Rs 2.5 crore and an annual revenue share equivalent to 4 per cent of radio companies' gross revenues.
The licence conditions will also prohibit radio companies from selling commercial airtime to advertisers. Service providers will also need to register every channel they air. News content will be permitted only from state-owned Doordarshan and All India Radio.
- 1 more annotations...
Financial Express : Cinemeta set to revive single-screen theatres
At a time when multiplex culture is on a rise, and the existence of gold old cineplexes is threatened, one company has taken the mantle to revive and renovate single-screen theatres, especially in small towns.
-
At a time when multiplex culture is on a rise, and the existence of gold old cineplexes is threatened, one company has taken the mantle to revive and renovate single-screen theatres, especially in small towns.
Cinemeta Entertainments is the latest venture from World Media Group (WMG). WMG has successful business ventures in different industries across the world like the Sony television network in India. WMG also has DTH operations in Australia and New Zealand amongst many others. Cinemeta is their first foray in the India. The company currently operates from Mumbai and has a regional office in Ahmedabad.
-
Earlier, companies like UFO Movies, Pyramid Saimira did digitise multiplexes and cineplexes. But no company has ever restored the original format of single-screen theatres. Cinemeta acquires single screen theatres from the theatre owners on a long lease of 7-10 years and then refurbishes the same.
The company also wants to get into film production and distribution and they believe that ‘Cinemagic’ will make way for other businesses. Cinemeta is running a chain, comprising 20 theatres in Gujarat currently, and is looking at acquiring and running about 500 theatres over the next three years.
“The renovation cost is need-based and varies from theatre to theatre. What Cinemeta ensures is clean toilets, comfortable seating and ambience and state-of-the-art digital technology at each of the theatres. Cinemeta manages these theatres and does not lease them out,” added Goswami.
Ranbaxy, Merck in pact for anti-infective drugs
Ranbaxy Laboratories on Monday announced it has signed a collaboration agreement with US-based Merck & Co for drug discovery and clinical development of products in the anti-infective field.
Both would work to develop clinically validated anti-bacterial and anti-fungal drug candidates, with Ranbaxy slated to get an undisclosed upfront sum and more than $100 million for each drug target, depending on successful development and regulatory approval. It will also be entitled to royalties under the five-year deal.
“Ranbaxy will carry out drug discovery and clinical development through phase II ‘a’ clinical trials, with Merck conducting development and commercialisation of drug candidates thereafter,” a company statement added. According to the agreement, the collaboration would begin this year with an initial term of five years and can be extended mutually thereafter by the parties.
-
Ranbaxy Laboratories on Monday announced it has signed a collaboration agreement with US-based Merck & Co for drug discovery and clinical development of products in the anti-infective field.
Both would work to develop clinically validated anti-bacterial and anti-fungal drug candidates, with Ranbaxy slated to get an undisclosed upfront sum and more than $100 million for each drug target, depending on successful development and regulatory approval. It will also be entitled to royalties under the five-year deal.
Financial Express : Pushing the pill
Stupid article in FE about how price controls are unnecessary because they are market-distortions. How about doing away with other oppressive market-distortions like Patents?
-
Posted online: Friday , May 16, 2008 at 2344 hrs
Pharmaceuticals is one of those rare industries where the interests of producers and those of consumers are seen to be at odds with one another. In India, low purchasing power of the average consumer exaggerates the apparent conflict between the producer striving for profit and consumers wanting low-priced medicines. What is generally not appreciated is that it is a battle for survival on both sides, not just the consumer. So, when the government plays referee and points to the logic of democracy to justify the need for drug price controls, it cannot be unmindful of pharma’s economic structure. Like most other interventionist policies, price controls are distortionary. While lowering the prices of drugs, they squeeze the industry’s profits.
Pharmaceutical firms opt for inlicensing to push sales
-
Ranbaxy Laboratories, Dr Reddy's Laboratories, Nicholas Piramal and other pharmaceutical companies are betting on inlicensing or strategic marketing tie-ups to help grow local sales after India banned copying of patented drugs.
-
ndian drug makers are forging alliances with overseas companies such as CD Pharma, Gnosis SpA, Crawford Healthcare and Syrio Pharma to sell drugs for chronic and acute cases.
These companies are doing so because it fetches higher profits vis-a-vis investments and is less risky after the world's second most populous nation adopted drug patents in 2005.
- 1 more annotations...
Pharma exports to miss government target
-
Rupee appreciation has hit the pharma industry as exports for the financial year 2007-08 are estimated to rise a moderate 7 per cent against the targetted 30 per cent growth. While the volumes may have gone up manifold, the concern of a dip in pharma exports in value terms is rising. Besides rupee appreciation, the dent in exports due to pricing pressure in the US, where a lot of products have gone off patent recently, also affected the exports.
-
Last year, pharmaceutical exports stood at $5.5 billion, according to Commercial Intelligence and Statistics (India) figures as against total exports of $125 billion, contributing around 5 per cent.
"The recession has also forced companies to offer high discounts in the US, which is the largest overseas market for India. The returns of the firms who are into value-added products are also affected," said Sunil Parekh, advisor to Crisil Solutions.
CIOL:He’s 17 single and a CEO!
-
NEW DELHI: Picture this, a seventeen-year old lad being a CEO of a 60-member team with projects in hand worth approximately Rs 2 crore and two offices in the US and one in UK. Handling the ancestral business- No, Suhas Gopinath formed Globals Inc.—a sweat funded organization on his own at the age of 14 from a cyber cafe. Though he wanted to be a vet, he holds no formal degree in IT and is just a class XII pass out.
"My class fellows used to make fun of me that I am a nerd and spent my time in a cyber cafe, but I knew I was chasing a big dream. An organization that will give chance to younger generations, which will not ask for years of work experience but the knowledge," he said. -
It all happened in the year 2000, when Gopinath applied for a domain—CoolHindustan.com, which is a horizontal portal mainly focused on NRIs to get them updated with the latest happenings in India. Highly impressed with the way Gopinath has made the portal, Network Solutions certified him as the youngest web-developer of the world and the rest as they say is history.
- 1 more annotations...
Selected Tags
Related Tags
Sponsored Links
Top Contributors
Groups interested in business
-
Free economics debates
Items: 4 | Visits: 166
Created by: Joel Liu
-
Sell FM
Sell, Sell, SellFM Talking ...
Items: 6 | Visits: 150
Created by: Ma Theresa Camartin
Highlighter, Sticky notes, Tagging, Groups and Network: integrated suite dramatically boosting research productivity. Learn more »
Join Diigo